GenSight Biologics S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Laurence Rodriguez
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 74, rue du Faubourg Saint-Antoine Paris IF France 75012
- IPO Date
- Jan 22, 2018
- Website
- gensight-biologics.com
- Similar Companies
- Business
- GenSight Biologics S.A. is a clinical-stage biopharmaceutical company specializing in developing and commercializing innovative gene therapies for the treatment of retinal neurodegenerative diseases and central nervous system disorders. The company focuses on ophthalmology and leverages two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics, to preserve or restore vision in patients with blinding retinal diseases. Its main product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy in Phase III clinical trials for Leber Hereditary Optic Neuropathy (LHON) caused by a mutated ND4 gene; and GS030, in Phase I/II clinical trials for retinitis pigmentosa with preclinical development for dry age-related macular degeneration. GenSight designs these therapies for administration via single intravitreal injections to each eye, aiming for sustainable functional visual recovery. Headquartered in Paris, France, and founded in the early 2010s, the company operates primarily in European and U.S. markets with ongoing efforts to out-license its therapies in additional global regions. Recent major developments include securing nearly €2 million in fundraising in late 2025 and obtaining regulatory approval from the French medicines safety agency (ANSM) for the GS010/LUMEVOQ REVISE dose-ranging study in France. The company is advancing technology transfer to a new manufacturing partner and preparing to finalize the Phase III trial protocol while pursuing strategic out-licensing opportunities outside the U.S. and Europe. Additionally, GenSight is exploring paid Early Access Programs worldwide and continues to execute its strategic business priorities for 2026, including restarting Compassionate Access Programs and extending clinical development timelines. These efforts signify important operational and strategic shifts as the company moves closer to commercial readiness for its lead gene therapies in retinal diseases.
Company News
Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
GenSight Biologics Announces a Successful €1.0 Million Fundraising Supported by Existing Shareholders
GenSight Biologics Reports Cash Position as of September 30, 2026
GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
GenSight Biologics Provides September 2026 Business Updates
Financial Analysis: Pyxis Oncology (NASDAQ:PYXS) and GenSight Biologics (OTCMKTS:GSGTF)
GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates
GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026
GenSight Biologics to Hold its Combined General Meeting on May 19, 2026
GenSight Biologics Announces Publication on Matching-Adjusted Indirect Comparison of Leber Hereditary Optic Neuropathy Treatments
GenSight Biologics Announces Annual General Meeting to Take Place on May 19, 2026
GenSight Biologics Announces the Filing of its 2025 Universal Registration Document
GenSight Biologics Reports Cash Position and Revenue from Early Access Program as of March 31, 2026
GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates
GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025
The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®
GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study
GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments
The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study
GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026